Skip to main content
Astria Therapeutics, Inc. logo

Astria Therapeutics, Inc. — Investor Relations & Filings

Ticker · ATXS ISIN · US04635X1028 US Manufacturing
Filings indexed 602 across all filing types
Latest filing 2025-06-13 Director's Dealing
Country US United States of America
Listing US ATXS

About Astria Therapeutics, Inc.

https://astriatx.com/

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for allergic and immunologic diseases. The company's mission is to provide life-changing treatments to patients and their families. Its lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein being developed as a potential long-acting, preventative treatment for Hereditary Angioedema (HAE). The company has reported positive initial proof-of-concept results from its ALPHA-STAR Phase 1b/2 clinical trial for STAR-0215. Astria Therapeutics is guided by patient needs to develop differentiated therapeutics that address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2025-06-13 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-06-12 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-06-12 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 11, 2025, for Astria Therapeutics, Inc. It reports on the Annual Meeting of Stockholders held on that date. The content includes details about the approval of an amendment to the stock incentive plan, election of directors, ratification of the independent auditor, and advisory vote on executive compensation. These are typical disclosures related to changes in board members and management, as well as shareholder voting results. The document is not a full annual report, audit report, or earnings release, but rather a current report focusing on governance and management changes and shareholder votes. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-06-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-15 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.